1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag

Marina Bozilenko resigns from Board of Directors of SynAct Pharma

MARKN.

SynAct Pharma AB (publ) ("SynAct") announced today Marina Bozilenko has notified the Board of her resignation as member of the Board of Directors due to personal reasons.

“We are grateful for Marina’s time and effort serving on the Board. She has been a valuable asset to SynAct. We wish her the best of luck,” said SynAct Chairman Uli Hacksell.

“I very much enjoyed working with the management team and Board of Directors of SynAct, but unfortunately my personal and professional commitments have increased a great deal and I am no longer able to contribute adequate time and effort to SynAct.  I resign my position with regret and wish the company and everyone involved a productive and successful future,” said Marina Bozilenko.

For further information, please contact:

Uli Hacksell
Chairman, SynAct Pharma AB
Email: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com. 

Attachments
Marina Bozilenko resigns from Board of Directors of SynAct Pharma

Datum 2024-02-27, kl 07:30
Källa MFN
Bifogade filer
Marina Bozilenko resigns from Board of Directors of SynAct Pharma
Affiliate
Kom igång med ditt sparande på bara några minuter! Hos Avanza handlar du aktier från 0 kr på Stockholmsbörsen och får tillbaka alla fondavgifter (ja, alla!) upp till 50 000 kr i samlat sparande. Kanske är det därför Avanza har Sveriges nöjdaste sparare 15 år i rad.
Investeringar innebär en risk